Frederic C Vigant

US Patent:

20220340927, Oct 27, 2022

Filed:

Aug 31, 2020

Appl. No.:

17/639281

Inventors:

- West Palm Beach FL, US
James Joseph Onuffer - Alameda CA, US
Farzad Haerizadeh - San Diego CA, US
Frederic Vigant - San Diego CA, US
Anirban Kundu - West-Bay, Grand Cayman, KY

Assignee:

Exuma Biotech Corp. - West Palm Beach FL

International Classification:

C12N 15/86
A61K 35/17
C07K 14/725

Abstract:

The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.

US Patent:

20220306698, Sep 29, 2022

Filed:

Apr 12, 2022

Appl. No.:

17/659007

Inventors:

- West Palm Beach FL, US
Ghiabe H. Guibinga - San Diego CA, US
Farzad Haerizadeh - San Diego CA, US
Frederic Vigant - West Palm Beach FL, US
Anirban Kundu - , US

Assignee:

Exuma Biotech Corp. - West Palm Beach FL

International Classification:

C07K 14/005
C12N 15/86
C07K 14/705
C07K 16/28
C07K 14/725
C07K 14/54
A61K 47/69
A61K 35/17
C12N 7/00

Abstract:

The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

US Patent:

20230111159, Apr 13, 2023

Filed:

Mar 4, 2021

Appl. No.:

17/905649

Inventors:

- West Palm Beach FL, US
Frederic Vigant - Lake Worth FL, US
Anirban Kundu - George Town, Grand Cayman, KY
Sidharth Kerkar - Boynton Beach FL, US
Gregory Schreiber - Palm Beach Gardens FL, US

Assignee:

Exuma Biotech Corp - West Palm Beach FL

International Classification:

A61K 35/17
C12N 15/86
A61K 35/15
A61K 45/06
C07K 14/725
A61P 35/00

Abstract:

The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.

US Patent:

20230044451, Feb 9, 2023

Filed:

Mar 1, 2022

Appl. No.:

17/684405

Inventors:

- West Palm Beach FL, US
Frederic VIGANT - West Palm Beach FL, US
Anirban KUNDU - West-Bay, KY
Sidharth KERKAR - Boynton Beach FL, US
Gregory SCHREIBER - Palm Beach Gardens FL, US

Assignee:

Exuma Biotech Corp. - West Palm Beach FL

International Classification:

A61K 35/17
A61P 35/00
A61K 9/00

Abstract:

The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.

US Patent:

20200255864, Aug 13, 2020

Filed:

Mar 18, 2020

Appl. No.:

16/823319

Inventors:

- West Palm Beach FL, US
James Joseph ONUFFER - West Palm Beach FL, US
Farzad HAERIZADEH - West Palm Beach FL, US
Frederic VIGANT - West Palm Beach FL, US
Anirban KUNDU - West Palm Beach FL, US

Assignee:

Exuma Biotech Corp. - West Palm Beach FL

International Classification:

C12N 15/86
C12N 7/00
C07K 16/28
C12N 5/0783

Abstract:

The present disclosure provides methods and compositions for genetically modifying lymphocytes and related methods that include genetically modifying T cells and/or NK cells. The methods use replication incompetent recombinant retroviral particles that comprise a pseudotyping element on their surface and optionally a membrane-bound T cell activation element, such as an anti-CD3, and encode one or more engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR). The methods can include contacting PBMCs with replication incompetent recombinant retroviral particles for various exemplary time periods, such as less than 24 hours or in some illustrative embodiments less than 15 minutes. In some aspects, the present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.